SCHEMBL1826085

SCHEMBL1826085

COC(=O)CC(c1cccc(OS(=O)(=O)c2ccc(C)cc2)c1)C(N)Cc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PLAU P00749 1/20 0.41
PLAT P00750 1/20 0.41
GAA P10253 2/20 0.40
MAPT P10636 2/20 0.40
G6PD P11413 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
P2RX7 Q99572 4/20 0.39
GPR17 Q13304 1/20 0.39
MTNR1A P48039 2/20 0.39
MTNR1B P49286 2/20 0.39
TP53 P04637 1/20 0.38
AKR1C3 P42330 1/20 0.37
AKR1C2 P52895 1/20 0.37
ENPP2 Q13822 1/20 0.37
KMT2A Q03164 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3575911 0.94 MTNR1A (0.41) MTNR1AMTNR1BKMT2ASMN1; SMN2
SCHEMBL1825023 0.92 P2RX7 (0.40) PLAUPLATGAAMAPTG6PD
SCHEMBL1825720 0.91 GPR17 (0.38) PLAUPLATGAAMAPTG6PD
SCHEMBL1826709 0.91 P2RX7 (0.44) PLAUPLATMAPTP2RX7KMT2A
SCHEMBL1824794 0.90 P2RX7 (0.43) PLAUPLATGAAMAPTG6PD
SCHEMBL1824044 0.89 P2RX7 (0.46) MAPTP2RX7ENPP2KMT2ASMN1; SMN2
SCHEMBL1823449 0.87 F10 (0.41) GAAMTNR1AMTNR1BKMT2ASMN1; SMN2
SCHEMBL1828158 0.86 LMNA (0.41) PLAUPLATGAAMAPTG6PD
SCHEMBL1827164 0.86 MTNR1A (0.43) MTNR1AMTNR1BKMT2ASMN1; SMN2
SCHEMBL1829278 0.85 PLAU (0.46) PLAUPLATGAAMAPTG6PD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2161254-B1 Intermediate for preparing a biaryl compound SUMITOMO CHEMICAL CO (JP) 2014-08-13 EP disclosed
EP-1481967-B1 PROCESS FOR THE PREPARATION OF BIARYL COMPOUNDS SUMITOMO CHEMICAL CO (JP) 2011-05-04 EP disclosed
US-7714157-B2 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-05-11 US disclosed
EP-2161254-A1 Intermediate for preparing a biaryl compound Sumitomo Chemical Company, Limited (JP) 2010-03-10 EP disclosed
US-20070270603-A1 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED 2007-11-22 US disclosed
US-7271280-B2 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-09-18 US disclosed
EP-1481967-A1 PROCESS FOR THE PREPARATION OF BIARYL COMPOUNDS Sumitomo Chemical Company, Limited (JP) 2004-12-01 EP disclosed
US-20040158093-A1 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040158093-A1 Process for preparing a biaryl compound CYP1B1, REL, CYP2F1 PLAU 4857/4885PLAT 4864/4885GAA 2170/4885
US-20070270603-A1 Process for preparing a biaryl compound CYP4A11, CYP4B1, CYP51A1 PLAU 4788/4885PLAT 4392/4885GAA 98/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.